Cargando…
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances in recent years, such as the identification of oncogenes and the use of immunotherapies, have changed the treatment of LUAD. Yet survival rat...
Autores principales: | Kleczko, Emily K., Kwak, Jeff W., Schenk, Erin L., Nemenoff, Raphael A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522855/ https://www.ncbi.nlm.nih.gov/pubmed/31134065 http://dx.doi.org/10.3389/fimmu.2019.00954 |
Ejemplares similares
-
Eicosanoids in Cancer: New Roles in Immunoregulation
por: Johnson, Amber M., et al.
Publicado: (2020) -
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms
por: Neuwelt, Alexander J, et al.
Publicado: (2020) -
Evaluation of KRAS(G12C) inhibitor responses in novel murine KRAS(G12C) lung cancer cell line models
por: Sisler, Daniel J., et al.
Publicado: (2023) -
Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases
por: Dobó, József, et al.
Publicado: (2018) -
Upregulation of complement proteins in lung cancer cells mediates tumor progression
por: Kleczko, Emily K., et al.
Publicado: (2023)